# FT836 CAR T-cell Therapy in Combination With Daratumumab in Patients With Relapsed and/or Refractory Multiple Myeloma

> **NCT07221032** · PHASE1 · NOT_YET_RECRUITING · sponsor: **Medical College of Wisconsin** · enrollment: 12 (estimated)

## Conditions studied

- Relapse Multiple Myeloma
- Refractory Multiple Myeloma

## Interventions

- **BIOLOGICAL:** FT836 CAR T cells (1 x 10^8 cells per dose)
- **BIOLOGICAL:** FT836 CAR T cells (3 x 108 cells per dose)
- **BIOLOGICAL:** FT836 CAR T cells (up to 9 x 108 cells per dose)
- **DRUG:** Daratumumab 16 mg/kg

## Key facts

- **NCT ID:** NCT07221032
- **Lead sponsor:** Medical College of Wisconsin
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-07
- **Primary completion:** 2028-03
- **Final completion:** 2030-03
- **Target enrollment:** 12 (ESTIMATED)
- **Last updated:** 2026-04-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07221032

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07221032, "FT836 CAR T-cell Therapy in Combination With Daratumumab in Patients With Relapsed and/or Refractory Multiple Myeloma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07221032. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*